Ouro Medicines Secures $120 Million for Innovative T-Cell Engager
Deal News | Jan 10, 2025 | Goodwin
Ouro Medicines has launched with $120 million in funding, with support from Monograph Capital and GSK plc. The Series A funding round was led by TPG Life Sciences Innovations, NEA, and Norwest Venture Partners, among others. The company has licensed a BCMA-directed, bispecific T cell engager, OM336, with legal representation from Goodwin. OM336 is at the forefront of Ouro's focus on therapies that leverage T cell engagers in B cell mediated diseases to induce immune resets. Ouro aims to advance a wide range of discovery programs. Based in San Francisco and set to launch in 2025, it is primarily backed by Monograph Capital, GSK, and leading investors. Goodwin's Life Sciences team played a central role in this significant funding and licensing process.
Sectors
- Biotechnology
- Life Sciences
- Pharmaceuticals
Geography
- United States – Ouro Medicines is based in San Francisco, California.
- United Kingdom – GSK, a partner in founding Ouro Medicines, is based in the UK.
- Hong Kong – Keymed Biosciences, from which Ouro licensed the OM336, is listed in Hong Kong.
Industry
- Biotechnology – Ouro Medicines is a biotechnology company focusing on immune reset therapeutics for chronic immune-mediated diseases.
- Life Sciences – The article involves the launch and licensing of a novel T-cell engager, placing it within the life sciences sector.
- Pharmaceuticals – The partnership with GSK and the development of a BCMA-directed therapy align with pharmaceutical innovations.
Financials
- $120 million – Funding raised during Ouro Medicines' Series A launch.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Ouro Medicines | Target company | Companies | Biotechnology company focused on immune reset therapeutics. |
| Monograph Capital | Investor and Founding Partner | Companies | Venture capital firm that helped found Ouro Medicines. |
| GSK plc | Partner and Investor | Companies | A global pharmaceutical company that partnered in the founding of Ouro Medicines. |
| TPG Life Sciences Innovations | Co-leader of Series A | Companies | Investment arm focusing on life sciences investments. |
| NEA | Co-leader of Series A | Companies | An American venture capital firm. |
| Norwest Venture Partners | Co-leader of Series A | Companies | Multi-stage investment firm. |
| Goodwin | Legal Advisor | Companies | Law firm that advised on the launch and licensing process. |
| Keymed Biosciences | Licensing Partner | Companies | Provider of the OM336 licensed by Ouro Medicines. |